Aug 5, 2015
“We are delighted to invite such a promising group of cutting-edge startups to Illumina Accelerator,” said Illumina Senior Vice President and Chief Technology Officer,
The selected startups for the spring 2015 funding cycle are:
PathoGn, Inc.is an infectious disease platform company based in Californiausing genomics and machine learning to build pathogen diagnostics and disease forecasting products for agricultural applications.
Biome Makers Inc.is a microbiome company founded by The Wine Guys, from Castile and Leon, Spain, introducing advanced genomics in the wine sector to transform the quality standards of vinification.
- Urology Diagnostics Incorporated is a genomics company from
Oregondeveloping noninvasive urine sequencing diagnostics for screening and monitoring cancer.
Each startup will receive seed investment, a subscription to Illumina’s NextBio translational genomics database, access to match funding through the
“We look forward to building upon the successes of our first graduates—Encoded Genomics, Inc.,
Illumina Accelerator strives to catalyze genomics innovation in the broader startup community. It aims to advance genomics by lowering the barrier to entry and expedite the time to market for entrepreneurs and early-stage companies that are working on scientifically and commercially promising next-generation sequencing applications. Startups are invited to join Illumina Accelerator twice a year.
Applications for the Illumina Accelerator Fall 2015 funding cycle are due by September 1, 2015. To apply, visit www.illumina.com/accelerator.
About Illumina, Inc.
This release may contain forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.